Skip to search formSkip to main contentSkip to account menu

CFI-400945

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial
CFI-400945 is a first-in-class oral inhibitor of polo-like kinase 4 (PLK4) that regulates centriole duplication. Primary… 
2018
2018
Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition
In “CFI-400945 is not a selective cellular PLK4 inhibitor,” Oegema et al. (1) raise thoughtful comments about our article (2). We… 
2018
2018
Abstract 1948: Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers
Despite current treatments, lung cancers remain a major public health problem. Innovative ways are needed to treat or prevent… 
2017
2017
A functional screening of the kinome identifies the Polo‐like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain
Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available… 
2016
2016
Abstract CT066: First-in-human phase I trial of the oral PLK4 inhibitor CFI-400945 in patients with advanced solid tumors
Background: CFI-400945 is a first-in-class, potent, selective, orally active inhibitor of Polo-like kinase 4 (PLK4) (Ki = 0.26 nM… 
2014
2014
A PLK4 inhibitor has single-agent activity in preclinical tumor models.
CFI-400945 is a potent, selective, orally bioavailable PLK4 inhibitor with antitumor activity in vivo. 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)